UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000015892
Receipt No. R000016519
Official scientific title of the study exploratory study for dilated cardiomyopathy using YS0001
Date of disclosure of the study information 2014/12/10
Last modified on 2018/06/13 (Ver. 7)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study exploratory study for dilated cardiomyopathy using YS0001
Title of the study (Brief title) exploratory study for dilated cardiomyopathy using YS0001
Region
Japan

Condition
Condition dilated cardiomyopathy
Classification by specialty
Cardiology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The objects are to evaluate the safety and validation of how to evaluate efficacy for autologous myoblast sheet
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes LVEF change at 26 week from treatment
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Culture of autologous skeletal myoblasts and engineering myoblast sheets. Transplantation of myoblast sheets to heart
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
19 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria DCM
NYHA Class => iii
Ejection fraction =<35%
Key exclusion criteria skeletal muscle disease
active infection (HIV,HBV,HCV,HTLV-1)
Cancer within the past 5 years
Target sample size 6

Research contact person
Name of lead principal investigator Yoshuki Sawa
Organization Osaka University hospital
Division name Cardiovascular surgery
Address 2-15 Yamadaoka, Suita, Osaka
TEL 06-6879-3154
Email sawa@surg1.med.osaka-u.ac.jp

Public contact
Name of contact person Shigeru Miyagawa
Organization Osaka University hospital
Division name Osaka University hospital
Address 2-15 Yamadaoka, Suita, Osaka
TEL 06-6879-3154
Homepage URL
Email miyagawa@surg1.med.osaka-u.ac.jp

Sponsor
Institute Department of Cardiovascular Surgery, Graduate School of medicine, Osaka University
Institute
Department

Funding Source
Organization Japan Agency for medical research and development
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2014 Year 12 Month 10 Day

Progress
Recruitment status Completed
Date of protocol fixation
2014 Year 05 Month 01 Day
Anticipated trial start date
2014 Year 11 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2014 Year 12 Month 10 Day
Last modified on
2018 Year 06 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000016519